Qinghao Zhang

Qinghao Zhang

Auto-generated profile, based on publicly available information

Qinghao Zhang

State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Science Advances
Verified
Journal Article
Closed access
KDKai Dai
Kai Dai
QZQinghao Zhang
Qinghao Zhang
SDShunshu Deng
Shunshu Deng
YYYuanman Yu
Yuanman Yu
FZFuwei Zhu
Fuwei Zhu
CLChangsheng Liu
Changsheng Liu
Cell therapies and regenerative medicine interventions require an adequate source of therapeutic cells. Here, we demonstrate that constructing in vivo osteo-organoids by implanting bone morphogenetic protein–2–loaded scaffolds into the internal muscle pocket near the femur of mice supports the growth and subsequent harvest of therapeutically useful cells including hematopoietic stem/progenitor cells (HSPCs), mesenchymal stem cells (MSCs), lymphocytes, and myeloid cells. Profiling of the in vivo osteo-organoid maturation process delineated three stages—fibroproliferation, osteochondral differentiation, and marrow generation—each of which entailed obvious changes in the organoid structure and cell type distribution. The MSCs harvested from the osteochondral differentiation stage mitigated carbon tetrachloride (CCl 4 )–induced chronic liver fibrosis in mice, while HSPCs and immune cells harvested during the marrow generation stage rapidly and effectively reconstituted the impaired peripheral and solid immune organs of irradiated mice. These findings demonstrate the therapeutic potentials of in vivo osteo-organoid–derived cells in cell therapies.